Eisai, a Japanese pharmaceutical company, has announced plans to invest £8m to create an additional packaging facility at its production plant in Hatfield, Hertfordshire, UK.
The plant serves as a global supply centre for new products such as antiepileptic agent Fycompa. It is operated by Eisai Manufacturing, the company’s manufacturing subsidiary in the UK.
Eisai president Haruo Naito said that the global centre for packaging at Hatfield is home to the company’s EMEA [Europe, Middle East and Africa] sales and marketing, R&D and manufacturing operations.
"This new investment is a vote of confidence in our EMEA Hatfield facility, Naito said. "The UK remains competitive as a location for advanced manufacturing."
The investment enables the company to strengthen its production functions with regards to its packaging capacity.
The company plans to handle the packaging of its investigational anticancer agent lenvatinib at the new facility, which will contain a packaging area for handling highly potent compounds.
The new facility will have a total floor space of around 2,900m². It will be located adjacent to the existing operating facility, which covers approximately 7,800m² in ground.
Construction of the facility is slated to commence in September, and is expected to be completed in mid-2014. The launch of operations is planned for September 2014.
UK Minister of State for the Department for Business, Innovation and Skills David Willetts said of the expansion: "Eisai’s decision to invest is great news for the UK and reflects the Government’s commitment to creating the best environment for life sciences."
Image: Hatfield pharma plant functions as a production and packaging base for European countries. Photo: courtesy of adamr